This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ACTG 320 was a completed phase 2 treatment study in HIV-infected patients. The registry identifies a total enrollment of 300 and lists abacavir sulfate, indinavir sulfate, and efavirenz as the study interventions.
| Feature | ACTG 320 |
|---|---|
| Study acronym | ACTG 320 |
| NCT identifier | NCT00001086 |
| Phase | Phase 2 |
| Status | Completed |
| Condition | HIV Infections |
| Population description | HIV-infected patients |
| Primary purpose | Treatment |
| Masking | None |
| Enrollment | 300 |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| Interventions | Indinavir sulfate; abacavir sulfate; efavirenz |
2. Clinical Question
The registry title identifies the study as an investigation of abacavir plus indinavir sulfate plus efavirenz in HIV-infected patients. The registry classifies the study's primary purpose as treatment.
Population
HIV-infected patients.
Intervention
Abacavir sulfate plus indinavir sulfate plus efavirenz, as identified in the registry title and intervention list.
Comparator
The ClinicalTrials.gov record represented here does not identify a comparator in the available trial data.
Primary question
What does treatment with abacavir plus indinavir sulfate plus efavirenz show in HIV-infected patients?
3. Trial Design
ACTG 320 is registered as a phase 2 study with a treatment primary purpose and no masking. The registry records an enrollment of 300 patients. The available record does not specify the allocation ratio, randomization procedure, comparator regimen, stratification factors, or treatment duration.
What the design tells us statistically
A phase 2 treatment study is generally positioned between initial clinical investigation and a larger confirmatory development program. The absence of masking is also statistically relevant because knowledge of treatment assignment can affect some measurements and behaviors, particularly outcomes involving clinical assessment, treatment adherence, reporting, or decisions made after treatment begins.
At the same time, design labels alone do not establish whether a particular treatment effect is unbiased or clinically important. Those conclusions require the actual allocation mechanism, comparator, endpoint definitions, analysis populations, and observed results.
4. Endpoints
The ClinicalTrials.gov record represented here contains no registered primary endpoints. Consequently, there is no endpoint definition or registry-specified time frame available to reproduce for ACTG 320.
| Endpoint information | Registry record |
|---|---|
| Registered primary endpoints | None listed |
| Endpoint definitions | Not reported in the available record |
| Endpoint time frames | Not reported in the available record |
| Posted statistical analyses | None |
5. Statistical Methodology
The registry identifies a treatment study but does not provide a registered primary endpoint or a posted statistical analysis. Therefore, the record does not establish a trial-specific inferential method such as a Cox model, logistic regression, ANCOVA, repeated-measures model, or a particular hypothesis test.
Why endpoint type determines the analysis
Clinical-trial statistical analysis begins with the endpoint. A binary endpoint, a continuous measurement, and a time-to-event endpoint contain different information and require different statistical approaches. The treatment comparison should therefore be defined after the endpoint and its analysis population are specified, rather than selecting a statistical test based only on the treatment names.
| Endpoint type | Typical analysis framework | Primary statistical question |
|---|---|---|
| Binary | Risk difference, risk ratio, odds ratio, or regression model for binary outcomes | How does the probability of the specified outcome differ between groups? |
| Continuous | Mean difference, ANCOVA, or an appropriate regression model | How does the outcome level differ between treatment groups? |
| Time-to-event | Kaplan-Meier estimation, log-rank testing, and/or Cox regression | How do event-free or survival times compare between groups? |
| Repeated measurements | Mixed-effects or other longitudinal models | How do outcome trajectories differ over time? |
Randomization and causal interpretation
If a study uses randomized treatment assignment, the randomized groups provide the principal framework for estimating the causal effect of assignment to treatment. The exact interpretation depends on the allocation procedure and the prespecified analysis population. Neither is described in the available registry information.
Unmasked treatment assignment
Because the registry specifies no masking, treatment assignment was not masked according to the registry classification. For objective laboratory outcomes, lack of masking may have less direct influence on measurement than for subjective outcomes. For clinical outcomes involving assessment or patient reporting, however, awareness of assignment can become a potential source of bias.
6. Planned Analysis
The ClinicalTrials.gov record contains no registered primary endpoints and no posted statistical analyses. Results have not been posted on ClinicalTrials.gov.
How an endpoint would ordinarily be analysed
The appropriate analysis depends on the endpoint definition. If the primary outcome were a binary clinical response, the analysis would ordinarily compare response probabilities between treatment groups and report an effect measure with a confidence interval. If the outcome were a continuous laboratory measurement, an analysis comparing treatment-group means or adjusted means could be appropriate. If the endpoint were time to an event, Kaplan-Meier methods and a time-to-event regression model such as Cox regression would commonly be considered.
The exact form of the effect depends on the endpoint: a difference, ratio, odds ratio, hazard ratio, or another prespecified estimand may be appropriate.
The key statistical requirement is that the endpoint, estimand, analysis population, censoring or missing-data rules, and hypothesis-testing framework be specified before interpreting the observed treatment comparison. Without those elements, a numerical treatment result cannot be assigned a precise statistical meaning.
7. Statistical Methods Explained
Why does the endpoint determine the statistical test?
Statistical methods are matched to the information carried by the endpoint. A response measured as yes/no is fundamentally different from a laboratory value measured on a continuous scale, and both differ from an outcome defined as time until an event. Choosing the analysis therefore starts with the clinical question and endpoint definition.
What would a confidence interval contribute?
A confidence interval quantifies statistical uncertainty around an estimated treatment effect under the specified statistical model and sampling framework. It is more informative than a point estimate alone because it communicates how precisely the treatment effect has been estimated.
Why is a p-value not an effect size?
A p-value addresses evidence against a specified null hypothesis under a statistical model. It does not describe the magnitude of a treatment effect. A clinically important effect can be estimated imprecisely, while a small effect can produce a small p-value in a sufficiently large study. Effect estimates and confidence intervals are therefore essential components of interpretation.
What would a hazard ratio mean if the endpoint were time to an event?
A hazard ratio compares estimated instantaneous event rates between treatment groups under a proportional-hazards model. A hazard ratio below 1 would indicate a lower estimated event hazard for the numerator group relative to the denominator group, subject to the model assumptions. It would not mean that the same percentage of every individual patient's risk had been reduced.
Why does lack of masking matter?
Masking can reduce the influence of knowledge of treatment assignment on behavior, reporting, treatment decisions, and outcome assessment. When masking is absent, the extent of potential bias depends strongly on whether the endpoint is objective or susceptible to subjective assessment.
Why is enrollment alone not enough to assess statistical power?
A sample size of 300 does not by itself determine whether a study could reliably detect a particular treatment effect. Power depends on factors such as the endpoint, event rate or variability, effect size of interest, allocation, significance level, and analysis method. Because these design parameters are not reported in the available record, statistical power cannot be characterized from enrollment alone.
8. Interpreting the Intervention Structure
The registry identifies three interventions: indinavir sulfate, abacavir sulfate, and efavirenz. The study title describes the investigation as abacavir plus indinavir sulfate plus efavirenz in HIV-infected patients.
Indinavir sulfate
- Intervention type: drug
- Listed in the registry as an intervention in ACTG 320
Abacavir sulfate
- Intervention type: drug
- Listed in the registry as an intervention in ACTG 320
Efavirenz
- Intervention type: drug
- Listed in the registry as an intervention in ACTG 320
Triple-drug regimen
- The study title describes abacavir plus indinavir sulfate plus efavirenz
- The available record does not identify a comparator regimen
From a statistical perspective, the distinction between an intervention component and a treatment regimen is important. If all three drugs are administered together as one randomized regimen, the treatment effect represents the effect of that regimen rather than an isolated effect attributable to any single drug. The available registry information does not provide enough detail to determine the exact allocation structure.
9. Analysis Populations and Missing Data
The available ClinicalTrials.gov record does not specify an intention-to-treat population, per-protocol population, safety population, or other analysis population. It also does not describe rules for treatment discontinuation, protocol deviations, missing observations, or censoring.
| Analysis component | Registry information |
|---|---|
| Intention-to-treat definition | Not reported |
| Per-protocol definition | Not reported |
| Safety population | Not reported |
| Missing-data method | Not reported |
| Imputation method | Not reported |
| Censoring rules | Not reported |
| Protocol-deviation handling | Not reported |
These details can materially affect statistical interpretation. For example, excluding participants after randomization can disrupt the balance created by randomization, while different assumptions about missing observations can change an estimated treatment effect. A complete statistical analysis therefore needs prespecified rules for these situations.
10. Multiplicity and Multiple Comparisons
No multiplicity strategy is reported in the available registry information. The record does not identify a hierarchy of primary and secondary endpoints, an alpha-allocation strategy, a gatekeeping procedure, or another method for controlling familywise type I error.
Why multiplicity matters
When several hypotheses are tested, the probability of obtaining at least one apparently positive result can exceed the nominal type I error rate unless the testing strategy accounts for the multiple comparisons.
Endpoint hierarchy
A prespecified hierarchy can determine which hypotheses are confirmatory and which are interpreted as supportive or exploratory.
Because no registered primary endpoints are listed, there is no endpoint hierarchy in the available record from which a confirmatory multiplicity framework can be reconstructed.
11. Interim Analysis and Sequential Monitoring
The available registry information does not describe an interim analysis plan, stopping boundaries, alpha spending, or sequential monitoring strategy.
In a trial that uses interim analyses, repeated examination of accumulating efficacy data can affect the overall type I error rate. Group-sequential methods address this issue by defining statistical boundaries or alpha-spending rules before the interim looks occur. Without a documented sequential design, no such framework should be attributed to ACTG 320.
12. Stratification and Covariate Adjustment
No randomization strata or prespecified covariate-adjustment factors are reported in the available registry information.
Stratification can be used to balance important prognostic factors across treatment groups and can also be incorporated into the primary analysis. Covariate adjustment can improve precision when clinically important baseline variables are strongly associated with the outcome. However, the statistical interpretation depends on the prespecified model and on whether the variables were measured before treatment assignment.
13. Bayesian Methods
No Bayesian statistical method is identified in the available registry information. There is no reported prior distribution, posterior analysis, Bayesian stopping rule, or posterior probability criterion.
A Bayesian analysis would combine prior information with observed data to produce a posterior distribution for the parameter of interest. For example, a posterior probability could be used to quantify the probability that a treatment effect exceeds a prespecified threshold. Such an analysis requires explicit specification of the prior and decision framework.
14. Safety and Adverse Events
The available record identifies the three drug interventions but does not provide serious adverse-event counts, adverse-event rates, treatment discontinuations due to adverse events, or other arm-specific safety results.
| Safety measure | Registry information |
|---|---|
| Serious adverse events by arm | Not reported |
| Adverse-event rates by arm | Not reported |
| Treatment discontinuations due to adverse events | Not reported |
| Deaths by arm | Not reported |
Safety analysis is statistically distinct from efficacy analysis. For randomized treatment studies, adverse events are commonly summarized using counts and percentages, with event definitions and exposure periods specified. For serious or uncommon events, the precision of percentage estimates can be limited when event counts are small.
15. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registry establishes a completed phase 2 treatment study with 300 enrolled patients and no masking. It does not provide registered primary endpoints or posted statistical analyses, so no trial-specific effect estimate or inferential result is available in the record.
Clinical interpretation
The study concerns abacavir sulfate, indinavir sulfate, and efavirenz in HIV-infected patients. The available registry information does not provide enough outcome detail to characterize efficacy or safety findings.
This distinction is important. A study can have a clearly defined intervention and substantial enrollment while still requiring endpoint-level information before its statistical evidence can be interpreted. The treatment question is clinically meaningful, but the statistical answer depends on the outcome definitions and comparisons that were actually prespecified and analysed.
16. What a Complete Statistical Analysis Would Need
For a treatment trial, the statistical analysis becomes interpretable when several linked pieces of information are available. These components define the estimand and establish how the observed data answer the clinical question.
| Component | Statistical role |
|---|---|
| Population | Defines the patients to whom the treatment comparison pertains. |
| Comparator | Defines the counterfactual treatment condition against which the intervention is evaluated. |
| Primary endpoint | Defines the principal outcome used to answer the primary question. |
| Time frame | Defines when the outcome is evaluated or the period over which events are counted. |
| Estimand | Defines the treatment effect being targeted, including the outcome, population, treatment conditions, and relevant intercurrent-event strategy. |
| Analysis population | Defines which enrolled or randomized participants contribute to the primary analysis. |
| Statistical model | Defines how the treatment effect and its uncertainty are estimated. |
| Missing-data rules | Define how incomplete observations are handled. |
| Multiplicity strategy | Defines how multiple hypotheses are handled when more than one inferential test is planned. |
ACTG 320's available registry record supplies the study identity, condition, phase, purpose, masking status, enrollment, sponsor, and intervention names, but does not supply these endpoint-level statistical details.
17. Limitations
- No registered primary endpoints: the available ClinicalTrials.gov record lists no registered primary endpoints, preventing endpoint-specific interpretation.
- No posted statistical analyses: the registry contains no posted statistical analyses for the study.
- No comparator specified: the available record does not identify the comparator treatment or regimen.
- No analysis population definitions: the record does not identify ITT, per-protocol, or safety populations.
- No missing-data strategy: the registry information does not describe imputation, censoring, or other missing-data handling.
- No multiplicity framework: there is no reported endpoint hierarchy or type I error-control strategy.
- No interim-analysis information: the available record does not identify interim looks or stopping boundaries.
- No safety results: arm-specific serious adverse-event counts and other safety outcomes are not reported in the available record.
- No efficacy estimates: the available record does not provide treatment-effect estimates, confidence intervals, p-values, or outcome event counts.
18. Why This Trial Matters Statistically
ACTG 320 provides a useful example of an important problem in clinical-trial interpretation: study registration information and statistical results are different layers of evidence. The registry establishes that a completed phase 2 treatment study enrolled 300 HIV-infected patients and identifies the intervention components, but the available record does not contain the endpoint and analysis information needed to quantify treatment effects.
| Concept | How it applies to ACTG 320 |
|---|---|
| Phase 2 design | The study is registered as phase 2. |
| Treatment purpose | The registry identifies treatment as the primary purpose. |
| Unmasked design | Masking is listed as none. |
| Sample size | Enrollment is 300. |
| Combination intervention | The study title identifies abacavir plus indinavir sulfate plus efavirenz. |
| Endpoint specification | No registered primary endpoints are listed in the available record. |
| Statistical analysis | No posted statistical analyses are listed. |
| Safety interpretation | Arm-specific serious adverse-event results are not reported in the available record. |
| Statistical uncertainty | No treatment-effect estimates or confidence intervals are reported. |
| Reproducibility | Endpoint definitions, analysis populations, missing-data rules, and inferential procedures are not reported in the available record. |
19. A Statistical Reading of the Registry Record
ACTG 320 is a completed phase 2 treatment study involving HIV-infected patients. The registry records 300 enrolled patients and lists indinavir sulfate, abacavir sulfate, and efavirenz as drug interventions.
The available record does not identify a comparator, registered primary endpoint, endpoint time frame, analysis population, statistical model, multiplicity strategy, interim-analysis procedure, missing-data method, or arm-specific safety result.
Statistical inference is inseparable from the endpoint and estimand being analysed. An enrollment number alone cannot tell us whether a treatment comparison was statistically significant, how large an effect was observed, or how precisely it was estimated.
20. Reading Treatment Effects Correctly
Although the available record does not contain a treatment-effect estimate for ACTG 320, the general principles used to interpret such estimates are important for understanding clinical-trial statistics.
Effect estimate
The effect estimate describes the magnitude and direction of the treatment comparison on the chosen scale. Depending on the endpoint, that scale might be an absolute difference, ratio, odds ratio, hazard ratio, or another prespecified measure.
Confidence interval
The confidence interval communicates uncertainty around the estimated treatment effect. A narrow interval indicates greater statistical precision than a wide interval under the same model and sampling framework. It does not describe the range of individual patient responses.
P-value
A p-value evaluates the compatibility of the observed data with a specified null hypothesis under the assumed statistical model. It does not measure clinical importance and should not be interpreted as the probability that the null hypothesis is true.
Absolute versus relative effects
Relative measures can be useful for comparing treatment effects across settings, while absolute measures describe the actual difference in outcome probability or event frequency. A complete clinical interpretation generally benefits from reporting the effect on a scale that is directly meaningful for the endpoint.
21. Sources
- ClinicalTrials.gov: ACTG 320, NCT00001086.
- PubMed: PubMed record associated with the study.
Continue through the Clinical Biostats knowledge graph
Explore the broader statistical methods used to design, analyse, and interpret clinical treatment studies.
22. Record Summary
ACTG 320 is registered as a completed phase 2 treatment study in HIV-infected patients, with 300 enrolled participants and no masking. The intervention list contains indinavir sulfate, abacavir sulfate, and efavirenz, while the study title describes abacavir plus indinavir sulfate plus efavirenz. The available ClinicalTrials.gov record does not list registered primary endpoints or posted statistical analyses.
From a statistical perspective, the most important lesson is that trial design information and treatment-effect evidence must be interpreted separately. Enrollment, phase, intervention, and masking establish the basic structure of a study; endpoint definitions, analysis populations, statistical models, effect estimates, confidence intervals, and hypothesis-testing procedures establish the evidence for a particular clinical outcome.